Home
Resources
Publications
Etofibrate but Not Controlled-Release Niacin Decreases LDL Cholesterol and Lipoprotein (A) in Type IIb Dyslipidemic Subjects

Etofibrate but Not Controlled-Release Niacin Decreases LDL Cholesterol and Lipoprotein (A) in Type IIb Dyslipidemic Subjects

A C Sposito, A P Mansur, R C Maranhão, C R Rodrigues-Sobrinho, O R Coelho, J A Ramires

Braz J Med Biol Res. 2001 Feb;34(2):177-82.

PMID: 11175492

Abstract:

Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hydrolases, both constituents are gradually released in a controlled-release manner. In this study, we compared the effects of etofibrate and controlled-release niacin on lipid profile and plasma lipoprotein (a) (Lp(a)) levels of patients with triglyceride levels of 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl. These patients were randomly assigned to a double-blind 16-week treatment period with etofibrate (500 mg twice daily, N = 14) or niacin (500 mg twice daily, N = 11). In both treatment groups total cholesterol, VLDL cholesterol and triglycerides were equally reduced and high-density lipoprotein cholesterol was increased. Etofibrate, but not niacin, reduced Lp(a) by 26% and low-density lipoprotein (LDL) cholesterol by 23%. The hybrid compound etofibrate produced a more effective reduction in plasma LDL cholesterol and Lp(a) levels than controlled-release niacin in type IIb dyslipidemic subjects.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP31637975	Etofibrate		31637-97-5	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: